Literature DB >> 16204618

B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.

Danielle Bonardelle1, Karim Benihoud, Nicole Kiger, Pierre Bobé.   

Abstract

The Fas/Fas ligand (FasL) pathway is one of the two major effector mechanisms of T cell-mediated cytotoxicity. To prevent nonspecific killing by lymphoid cells, FasL expression on the cell surface of immune effector cells is strictly regulated. However, MRL/lpr autoimmune-prone mice massively overexpress FasL on their T lymphocytes, which render them able to kill Fas+ targets in vitro and in vivo. It is surprising that we show in the present work that B lymphocytes purified from MRL/lpr spleen cells express FasL to the same extent as T cells at the mRNA and protein level. These B cells are potent cytotoxic effectors against Fas+ but not Fas- targets. The B lymphocyte effectors were used ex vivo without any in vitro activation by B cell stimuli. Furthermore, we found that MRL/lpr B lymphocytes have the same cytotoxic potential as natural killer cells, which have been characterized as potent, Fas-mediated, cytotoxic effectors. The level of membrane-anchored FasL increases with the size of the B cell and cell-surface activation marker CD69 expression, indicating that the expression of FasL is up-regulated in parallel with the activation state of the B cell. The activated B cell population contained the major cytotoxic activity, and a minor part was associated with CD138/Syndecan-1+ plasma cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204618     DOI: 10.1189/jlb.0904536

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  13 in total

Review 1.  Killer B lymphocytes: the evidence and the potential.

Authors:  Steven K Lundy
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

Review 2.  Multiple mechanisms of immune suppression by B lymphocytes.

Authors:  Matthew W Klinker; Steven K Lundy
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 3.  B cells with regulatory properties in transplantation tolerance.

Authors:  Justine Durand; Elise Chiffoleau
Journal:  World J Transplant       Date:  2015-12-24

4.  Increased killer B cells in chronic HCV infection may lead to autoimmunity and increased viral load.

Authors:  N Eiza; E Zuckerman; M Carlebach; T Rainis; Y Goldberg; Z Vadasz
Journal:  Clin Exp Immunol       Date:  2018-08       Impact factor: 4.330

5.  Characterization and Activation of Fas Ligand-Producing Mouse B Cells and Their Killer Exosomes.

Authors:  Steven K Lundy; Sophina H Taitano; Luciën E P M van der Vlugt
Journal:  Methods Mol Biol       Date:  2021

6.  Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.

Authors:  Shang-xue Yan; Xiao-mei Deng; Qing-tong Wang; Xiao-jing Sun; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-10-12       Impact factor: 6.150

Review 7.  Immunosuppressive Mechanisms of Regulatory B Cells.

Authors:  Diego Catalán; Miguel Andrés Mansilla; Ashley Ferrier; Lilian Soto; Kristine Oleinika; Juan Carlos Aguillón; Octavio Aravena
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

8.  Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis.

Authors:  Steven K Lundy; David A Fox
Journal:  Arthritis Res Ther       Date:  2009-08-25       Impact factor: 5.156

9.  Loss of P2X7 receptor plasma membrane expression and function in pathogenic B220+ double-negative T lymphocytes of autoimmune MRL/lpr mice.

Authors:  Sylvain M Le Gall; Julie Legrand; Mohcine Benbijja; Hanaa Safya; Karim Benihoud; Jean M Kanellopoulos; Pierre Bobé
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

10.  Interleukin-5 supports the expansion of fas ligand-expressing killer B cells that induce antigen-specific apoptosis of CD4(+) T cells and secrete interleukin-10.

Authors:  Matthew W Klinker; Tamra J Reed; David A Fox; Steven K Lundy
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.